2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2540

Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2474

Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2550

Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2117

Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2276

Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2720

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2473

Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2538

Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2314

Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2707

Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2231

Improving Compliance with Screening for Osteoporosis in Elderly Women

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2380

Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2283

Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2423

In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2328

In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].